Drug Trial Radar · NCT04757974
Low-dose Fostemsavir Extended Release Relative Bioavailability Study
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 5, 2021
Primary completion
Jul 31, 2021
Study completion Jul 31, 2021
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two-part study. Part 1 will evaluate relative bioavailability of temsavir (TMR) following single dose administration of the reference fostemsavir (FTR) compared to two low-dose ER tablet formulations of FTR. In Part 2, the effect of food on the bioavailability of TMR will be assessed on the selected low-dose ER tablet formulation from Part 1.
Conditions
- HIV Infections
Interventions
Fostemsavir 600 mgDrug
Fostemsavir tablets will be administered via oral route.
Fostemsavir 200 mgDrug
Fostemsavir tablets will be administered via oral route.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable time point (AUC[0-t]) of temsavirTime frame: Predose (Day 1) until 72 hour post dose
- Part 1: AUC from time zero extrapolated to infinite time (AUC[0-infinity]) of temsavirTime frame: Predose (Day 1) until 72 hour post dose
- Part 1: Maximum observed plasma concentration (Cmax)Time frame: Predose (Day 1) until 72 hour post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.